EGFR

(redirected from Epidermal growth factor receptor)
Also found in: Medical, Wikipedia.
AcronymDefinition
EGFREpidermal Growth Factor Receptor
EGFREpidermal Growth Factor Receptor (a kinase enzyme)
EGFREstimated Glomerular Filtration Rate
EGFREndothelial Growth Factor Receptor
EGFREpidermal Growth Factor Receptor Concentration
EGFRExpression of Growth Factor Receptor (cancer research)
EGFREnhanced Growth Factor Receptor
References in periodicals archive ?
In addition, the research team found that Iressa, a cancer drug that blocks the epidermal growth factor receptor, effectively stopped the proliferation caused by amphiregulin.
Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results.
Comment: Tarceva targets the human epidermal growth factor receptor (HER1 or EGFR) pathway, which is "critical" to cell growth in NSCLC and other cancers, according to Genentech.
Cetuximab targets epidermal growth factor receptors (EGFRs) expressed in normal and neoplastic tissues.
Epidermal Growth Factor Receptor (EGFR) inhibitors are currently used to treat non-small cell lung cancer, pancreatic, colorectal, and head & neck cancer.
Erbitux (cetuximab) is the first and only approved IgG1 monoclonal antibody that specifically blocks the epidermal growth factor receptor found in tumours.
During the poster presentation session on June 5th, TMD presented data from their ongoing tdap(TM) study - Heterogeneity of Epidermal Growth Factor Receptor (EGFR) Expression and Variation in Immunohistochemistry (IHC) Testing May Affect Access to EGFR-Targeted Therapy in Patients with Advanced Colorectal Cancer (CRC).
Food and Drug Administration (FDA) has accepted the Biologic License Application (BLA) for panitumumab, an investigational fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFr) and has granted Priority Review.
One region, known as the fragment binding antigen or Fab region, is designed to inhibit the function of a molecular structure called the epidermal growth factor receptor (EGFR), which is found on normal cells and tumor cells.
Amgen (NASDAQ:AMGN), the world's largest biotechnology company, today announced interim results from two Phase 2 studies of panitumumab, an investigational fully human monoclonal antibody that targets the epidermal growth factor receptor (EGFr).
The second antibody, IMC-11F8, is a high affinity antibody that blocks ligand-dependent activation of the epidermal growth factor receptor (EGFR).
Full browser ?